Health Care [ 3/12 ] | Life Sciences Tools & Services [ 29/74 ]
NASDAQ | Common Stock
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries.
It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS).
The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.
The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts.
The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services.
The company operates in the United States, the Netherlands, and internationally.
The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021.
Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 9, 24 | -0.73 Decreased by -92.11% | -0.97 Increased by +25.13% |
| Aug 8, 24 | -1.00 Decreased by -1.53 K% | -0.83 Decreased by -20.48% |
| May 15, 24 | -1.86 Decreased by -376.92% | -0.54 Decreased by -244.44% |
| Feb 7, 24 | -0.60 Decreased by -87.50% | -0.85 Increased by +29.41% |
| Dec 11, 23 | -0.38 Increased by +96.02% | -0.33 Decreased by -15.15% |
| Aug 10, 23 | 0.07 Increased by +75.00% | -0.10 Increased by +170.00% |
| May 11, 23 | -0.39 Decreased by -62.50% | -0.42 Increased by +7.14% |
| Jan 10, 23 | -0.32 Decreased by -154.24% | -0.37 Increased by +13.51% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 130.42 M Decreased by -7.33% | -18.89 M Decreased by -95.50% | Decreased by -14.49% Decreased by -110.97% |
| Jun 30, 24 | 105.79 M Decreased by -32.82% | -26.09 M Decreased by -1.52 K% | Decreased by -24.66% Decreased by -2.21 K% |
| Mar 31, 24 | 119.03 M Decreased by -21.41% | -48.08 M Decreased by -399.31% | Decreased by -40.39% Decreased by -535.34% |
| Dec 31, 23 | 135.50 M Decreased by -9.95% | -15.39 M Increased by +93.68% | Decreased by -11.36% Increased by +92.99% |
| Sep 30, 23 | 140.74 M Decreased by -6.46% | -9.66 M Increased by +96.04% | Decreased by -6.87% Increased by +95.77% |
| Jun 30, 23 | 157.47 M Decreased by -8.80% | 1.84 M Increased by +149.36% | Increased by +1.17% Increased by +154.12% |
| Mar 31, 23 | 151.46 M Increased by +7.95% | -9.63 M Decreased by -44.49% | Decreased by -6.36% Decreased by -33.86% |
| Dec 31, 22 | 150.47 M Increased by +78.68% | -243.63 M Decreased by -192.08% | Decreased by -161.92% Decreased by -63.47% |